IMPORTANCE Attention-deficit/hyperactivity disorder (ADHD) research has long focused on the dopaminergic system's contribution to pathogenesis, although the results have been inconclusive. However, a case has been made for the involvement of the noradrenergic system, which modulates cognitive processes, such as arousal, working memory, and response inhibition, all of which are typically affected in ADHD. Furthermore, the norepinephrine transporter (NET) is an important target for frequently prescribed medication in ADHD. Therefore, the NET is suggested to play a critical role in ADHD.
many individuals with ADHD routinely receive psychopharmacologic treatment.
Patients with ADHD often receive methylphenidate hydrochloride and amphetamine sulfate, which are stimulant medications that enhance dopaminergic and noradrenergic signaling. Alternatively, atomoxetine hydrochloride, which is a nonstimulant drug that blocks the norepinephrine transporter (NET), is used. By blocking the NET, atomoxetine affects noradrenergic signaling and, particularly in brain regions lacking the dopamine transporter, increases dopaminergic transmission. 8, 9 Treatment using methylphenidate, amphetamine, and atomoxetine is associated with improvement of clinical symptoms and performance in controlled tasks eliciting executive functions, such as inhibitory control, and of cognitive functions, such as working memory and attention.
10-13
Although amphetamine and methylphenidate have been suggested [14] [15] [16] to exert therapeutic efficacy via an increase in extracellular dopamine, they also have been shown 16, 17 to modulate noradrenergic neurotransmission, which may be therapeutically relevant. Methylphenidate may dose-dependently block the NET, thereby regulating noradrenergic and dopamine reuptake. 18, 19 In a similar manner, atomoxetine has been shown 20 to facilitate therapeutic response by binding the NET.
In addition, quetiapine fumarate, which is not used as an ADHD medication but has been shown 21 to improve cognitive function in patients with psychosis, was shown 22 to bind to the NET.
Ultimately, facilitation of therapeutic response by catecholamines in general and the NET in particular suggests that these systems may be relevant to ADHD. Furthermore, ADHD symptoms have long been attributed to abnormalities within the frontostriatal and frontoparietal networks implicated in executive functions 23 modulated by catecholaminergic systems. 24, 25 The noradrenergic system, which originates in the locus coeruleus and exerts virtually ubiquitous influence within the brain, modulates, among other cortical regions, the prefrontal cortex through dynamic adaption of tonic and phasic firing. 26 Studies 27,28 displaying improvement of such symptoms by application of α 2 agonists further link noradrenergic influence on prefrontal cortexmediated cognitive functions to ADHD. More assertive investigation of underlying neurobiological correlates is made possible through positron emission tomography (PET) imaging studies, which have focused on ADHD-related changes in the dopaminergic system. Although changes in dopamine transporter [29] [30] [31] and dopamine D 2 and D 3 receptor levels and distribution 29,32,33 as well as dopamine release 34, 35 have been investigated, the results remain inconclusive. However, the proposition that methylphenidate, amphetamine, and atomoxetine may induce therapeutic response via NET modulation suggests that noradrenergic factors, and more specifically changes in the NET, may play a role in ADHD pathogenesis. Therefore, we proposed a thorough investigation of ADHDrelated NET distribution, as has been performed for the serotonin transporter and dopamine transporter. To address this issue, we used the recently developed NET-specific radiotracer (S,S)-
methoxyphenoxy)benzyl)morpholine], which has been successfully applied in healthy control groups. 36 To investigate the role of noradrenergic changes within ADHD, NET imaging was carried out in a region of interest (ROI) approach focusing on brain areas integral to the noradrenergic system.
Methods

Participants
Written informed consent was obtained from all participants after detailed explanation of the study protocol, and the participants received financial reimbursement. 
Data Acquisition
All PET was carried out at the Department of Biomedical I m a g i ng a n d I m a g e -G u i d e d T h e r a p y, D i v i s i o n o f Nuclear Medicine, Medical University of Vienna, using a full-ring scanner (GE Advance; General Electric Medical Systems) in a 3-dimensional acquisition mode. and 440.4 (233.7) GBq/μmoL (controls) (P = .15, 2-tailed, paired t test). Brain radioactivity was measured in a series of 6 consecutive time frames lasting 10 minutes each in the interval of 120 to 180 minutes after administration of the bolus. Acquired data were reconstructed in volumes consisting of 35 transaxial sections (128 × 128 matrix) using an iterative filtered back-projection algorithm 46 with a spatial resolution of 4.36 mm full-width at half of the maximum 1 cm next to the center of the field of view. For coregistration, MRIs were acquired from all participants on a 3-T scanner (Achieva; Philips) using a 3-dimensional T1 fast field echoweighted sequence, yielding 0.88-mm section thickness and in-plane resolution of 0.8 × 0.8 mm.
Data Quantification
Each time frame of the dynamic PET scan was realigned to the mean of frames with no head motion, identified by visual inspection. Subsequently, each summed image (PET integral image from realigned data) was coregistered (rigid body transformation) to each participant's MRI using a mutual information algorithm implemented in SPM8 (Wellcome Trust Centre for Neuroimaging; http://www.fil.ion.ucl.ac.uk/spm/). 
Statistical Analysis
Data were analyzed using linear mixed models for the outcome measure NET BP ND with the ROI as a repeated factor; participant groups, sex, and ROI as fixed factors; and participants and matched participant pairs as random factors. A separate model was calculated for the 6 ROIs based on the Hammers Maximum Probability Atlas and for the 13 thalamic subnuclei. Likewise, manually delineated ROIs were assessed in 2 additional models: one using the 4 atlas-based ROIs and the other using the 2 individual-based ROIs. Fixed effects were included in the model in a multifactorial approach, whereas interaction effects were dropped in instances of nonsignificance. In cases of significant interactions or main effects, post hoc pairwise comparisons were computed and Bonferroni correction was performed for multiple comparisons. In a second exploratory approach to examine the effects of handedness, smoking status, and age, a mixed model was calculated using a stepwise procedure with backward elimination, starting with all candidate variables (including participant groups and ROIs) and followed by a stepwise deletion of interactions and variables with the largest P values. Finally, mixed-models analyses were also applied to investigate the effects of the clinical variables inattentiveness and hyperactivity/impulsivity, which were assessed with the CAARS-Investigator Screening Version. According to the Akaike information criterion, 52 repeated measurements were modeled using a compound symmetric covariance structure. As an exploratory analysis, we also compared NET BP ND between patients and controls at the voxel level using SPM8 (paired t test); SPSS, version 19.0 for Windows (SPSS Inc), was used for statistical computations. The 2-tailed significance level was set at P = .05. Region of interest and voxel-wise analysis results were corrected for multiple comparisons using Bonferroni and false discovery rate analysis, respectively.
Results
Linear mixed-models analysis revealed an expected main effect of ROI (F 5,215 = 117.71; P < .001) but no main effects of participant group (F 1,41 <0.01; P = .96) ( Table 2 and Figure 1 ) or sex (F 1,41 <0.01; P = .98) and no interaction effects (all P > .10). Post hoc pairwise comparisons revealed significant NET BP ND differences between the 6 tested brain regions (atlas-generated ROIs; P < .05, corrected) except for the comparisons of midbrain with pallidum and putamen with cerebellum, which had similar binding values (Table 2 and Figure 2 ). Analogous results were obtained from the 2 mixed models for the manually delineated ROIs, which showed main effects of ROI but no main effects of group and sex and no interaction effects. Similarly, the linear mixed model for NET binding within the thalamic subnuclei revealed a main effect of ROI (F 12,516 = 105.53; P < .001) but no main effect of group (F 1,41 = 0.08; P = .78) or sex (F 1,41 = 0.39; P = .54) and no interaction effects (all P > .10). In addition, there was no significant difference in NET binding between patients with ADHD and the controls in any brain region at the voxel level (all P > .05, corrected). When investigating the potential effects of handedness, smoking status, and age, mixed-models analysis for ROI NET BP ND based on the Hammers Maximum Probability Atlas revealed an interaction effect between ROI and age (F 5,190 = 9.94; P < .001) in addition to a main effect of ROI but no main effect of age. Post hoc correlation analyses between regional NET BP ND and age revealed strong negative correlations in the thalamus (R 2 = 0.29; P < .01 corrected) and midbrain (R 2 = 0.18 P < .01 corrected) (Figure 3 ), but these correlations did not differ significantly between the control and ADHD groups. Handedness and smoking status had no effect on NET BP ND , nor did they lead to any significant interactions. Comparable results were observed for manually delineated ROIs, which showed strong negative correlations between NET BP ND and age in the midbrain (R 2 = 0.28; P < .01 corrected), locus coeruleus (R 2 = 0.26; P < .01 corrected), and hypothalamus (R 2 = 0.26; P < .01 cor- There were no significant differences between the ADHD and control groups in NET BP ND (a unitless measure) in patients with attention-deficit/hyperactivity disorder (ADHD) and healthy control participants. The heavy rule within the scatterplots indicates the mean; thin rules, SD.
rected). In addition, no main or interaction effects were observed for clinical variables (CAARS-Inattentiveness and CAARS-Hyperactivity/Impulsivity) and ROI BP ND . Finally, exclusion of 3 patients with previous methylphenidate intake in childhood (intake duration was 4, 5, and 7 years) and 2 patients with previous atomoxetine consumption in adulthood (intake duration was 5 and 6 months) did not change NET binding results. We further excluded 2 patients exhibiting predominantly inattentive symptoms and 1 exhibiting predominantly hyperactivity/impulsivity symptoms and, in a separate analysis, 2 patients with past drug abuse. Exclusion of these participants did not change the results.
Discussion
To our knowledge, this is the first PET study to investigate the differences in brain NET distribution and availability in adults with ADHD. We found no significant differences in the BP ND of (S,S)-[ 18 F]FMeNER-D 2 between the patients with ADHD and the controls. Furthermore, exclusion of patients exhibiting either predominantly inattentive or predominantly hyperactivity/impulsivity subtypes and patients with previous ADHD pharmacotherapy or past drug abuse did not change the results. Our findings validate previous studies 53 showing an age-related decrease in brain NET availability in the healthy human brain and show an agerelated decrease in brain NET availability in adults with ADHD. Randomized placebo-controlled studies 54-56 have repeatedly shown that methylphenidate, amphetamine, and atomoxetine significantly decrease symptoms in adult ADHD patient cohorts. The clinical efficacy of a pharmaceutical agent implies that the mechanism of action through which it attains a response is relevant to the neurobiology and resulting symptoms of a particular disease. Therefore, modulation of the noradrenergic system by these 3 drugs suggests noradrenergic abnormalities in ADHD.
Executive functions, such as response inhibition, vigilance, working memory, and planning, are typically impaired in ADHD. 57, 58 The association of these functions with the prefrontal cortex, which exhibits pronounced noradrenergic innervation, once again implicates, more generally, the noradrenergic system in ADHD. 59 However, investigations into the involvement of other neurotransmitter systems in ADHD are similarly inconclusive. First, current data available on the dopaminergic contribution to ADHD are wrought with inconsistency. As is the case with the NET, therapeutic doses of methylphenidate have been shown 60,61 using PET to reduce radiotracer striatal dopamine transporter binding in a dose-dependent manner in healthy individuals. Methylphenidate-induced dopamine transporter blockade has been causally linked to an 67, 70 showed no difference in serotonin transporter distribution between patients with ADHD and healthy controls. Therefore, although existing evidence neither affirms nor disproves the neurotransmitter systems discussed above to be involved in ADHD, background pharmacologic evidence supporting, in particular, dopaminergic and noradrenergic contribution, is strong. It was recently suggested by del Campo et al 32 that ADHD-related dopaminergic changes may reflect associated symptoms rather than a disease-specific endophenotype. Therefore, approaches that step away from the concept of endophenotypical noradrenergic changes in ADHD and focus on changes associated with ADHD symptoms may prove to be valuable. However, exclusion of patients exhibiting the predominantly inattentive subtype and predominantly hyperactivity/ impulsivity subtype of ADHD did not change our main findings, strongly suggesting that our results reflect a lack of changes in the brain NET level in ADHD in general rather than a subtype-specific phenomenon. In this context, future studies may profit from incorporating cognitive tests and genetic data into analysis for further symptom-oriented and phenotypical classification of participants. Despite the well-established link between modulation of the NET and improvement of ADHD symptoms, supported by recent genetic studies 71 implicating the NET gene in ADHD, our study did not reveal differences in NET distribution between patients with ADHD and the controls. Atomoxetine, methylphenidate, and amphetamine modulation of the NET has yet to be investigated in individuals with ADHD. Therefore, one cannot exclude the possibility that pharmacologic mechanisms of stimulants and nonstimulants in patients with ADHD differ from those in healthy individuals, as has been proposed to be the case by some investigators, 72 although not by others. 73 However, the results of the present study may also be interpreted to suggest that, despite the proposed involvement in the efficacy of ADHD pharmaceuticals, the NET may not be integral to ADHD. Nevertheless, the missing difference in the NET between groups would not necessarily exclude the involvement of other components of the noradrenergic system in ADHD. In fact, guanfacine hydrochloride, an α 2 adrenoceptor agonist and novel ADHD treatment option, appears to be a good treatment alternative to stimulant and nonstimulant medications. 74 Although this finding does not necessarily imply that α 2 adrenoceptors are integral to ADHD, it again underlines the link between noradrenergic innervation and ADHD symptoms while proposing that ADHD symptoms may also be modulated by other noradrenergic elements. However, several characteristics attributed to the transporter limit PET investigations into the role of the NET in ADHD and therefore must be considered. First, although cortical and subcortical regions express NET, the levels of expression are generally considered to be low, 36 , showing only slight differences between the locus coeruleus and thalamus. These method-dependent differences speak for distortion of locus coeruleus values through partial volume effects. In addition, we cannot exclude the possibility that similar effects may influence NET values measured in the small thalamic subnuclei evaluated.
Conclusions
The lack of differences observed in NET distribution between patients with ADHD and control participants does not exclude noradrenergic abnormalities in ADHD, since only one molecular aspect and not all regional aspects of the noradrenergic system were investigated. To further clarify NET involvement in ADHD, cortical brain regions must be investigated and occupancy studies must be carried out to solidify the relationship between pharmacologically induced clinical improvement and noradrenergic changes. 
